



IFW

Dkt. #627-B-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vladimir BAKHUTASHVILI  
U.S. Serial No.: 10/795,819  
Filed : March 8, 2004  
For : AMNIOTIC APOPTOSIS MODULATING SUBSTANCES

Law Offices of Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, New York 11357

February 22, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-145

Sir/Madam:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant hereby submits this Supplemental Information Disclosure Statement in accordance with his duty of disclosure under 37 C.F.R. §1.56. Applicant originally filed an Information Disclosure Statement for the above-identified application on March 8, 2004. Applicant would like to direct the Examiner's attention to the following references which are listed below as **Exhibit 1-2** and on Form PTO/SB/08B (**Exhibit A**). Applicant's attorney's office may be contacted in the event that the Examiner would like a copy of all references filed with the March 8, 2004 Information Disclosure Statement. The following reference is attached:

1. PCT Notification of Transmittal of International Preliminary Examination Report and International Preliminary Examination Report for Lajor Bio Tech, Inc., International Application No. PCT/US01/41666, Filed on August 9, 2001, Dated January 21, 2005. [**Exhibit 1**]
2. Wilson et al., The Effect of Interleukin-16 and Its Precursor on T Lymphocyte Activation and Growth. Growth

Applicant : Vladimir BAKHUTASHVILI  
U.S. Serial No.: 10/795,819  
Filing Date : March 8, 2004  
Page : 2

Factors. June 2004, Vol. 22, No. 2, pages 97-104.

[Exhibit 2]

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of the SIDS. However, if a fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

I hereby certify that this paper is being deposited this date with the U.S. Postal Service with sufficient postage for first class mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Albert Wai-Kit Chan

Albert Wai-Kit Chan  
Reg. No. 36,479


2/22/05

Date

Respectfully submitted,

Albert Wai-Kit Chan

Albert Wai-Kit Chan  
Registration No. 36,479  
Attorney for Applicant  
Law Offices of  
Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, New York 11357  
Tel: (718) 357-8836  
Fax: (718) 357-8615  
E-mail: kitchanlaw@aol.com



PTO/SB/08B (04-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449, PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

### Complete if Known

Application Number	10/795,819
Filing Date	March 8, 2004
First Named Inventor	Vladimir BAKHUTASHVILI
Art Unit	NOT YET KNOWN
Examiner Name	NOT YET KNOWN
Attorney Docket Number	627-B-US

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	1. PCT Notification of Transmittal of International Preliminary Examination Report and International Preliminary Examination Report for Lajor Bio Tech, Inc., International Application No. PCT/US01/41666, Filed on August 9, 2001, Dated January 21, 2005	
	2	Wilson et al., The Effect of Interleukin-16 and Its Precursor on T Lymphocyte Activation and Growth. Growth Factors. June 2004, Vol. 22, No. 2, pages 97-104.	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.